Recombinant VWF
Alternative Names: Vonvendi
Recombinant von Willebrand factor (rVWF), marketed as Vonvendi, is a non-plasma-derived treatment used for patients with von Willebrand disease (VWD) who do not respond to desmopressin. It contains only VWF, allowing for precise control of factor VIII levels, which is especially helpful for patients at risk of FVIII accumulation or thrombosis.
Vonvendi is given by intravenous infusion and is effective in managing surgery, acute bleeding, and severe VWD (types 2 and 3). Unlike plasma-derived products, it eliminates the risk of blood-borne infections. Patients or providers may choose it over other treatments when avoiding plasma products is preferred or when more flexible, targeted replacement of VWF and FVIII is needed.
Treatment Type: Prescription Medication
Treatment Class: N/A
Treatment Modality: N/A
Review Summary
Based on the review, Recombinant VWF (Vonvendi) appears to be an effective treatment for von Willebrand disease, particularly for patients with inhibitors to plasma-derived proteins. It offers flexible dosing, can be paired with recombinant FVIII, and is recommended by guidelines for precise VWF and FVIII management. The single review gave it a 4 out of 5 rating, suggesting a positive assessment of its clinical utility.
This summary was generated by users' reviews
Breakdown by Category
Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.
Explore various treatment options to empower yourself in making a well-informed choice.
Choose treatments from the menu above to see how they compare side by side.
Choose treatments from the menu above to see how they compare side by side.
Choose treatments from the menu above to see how they compare side by side.
AI Summary of User Experiences
Not medical advice.
Based on the review, Recombinant VWF (Vonvendi) appears to be an effective treatment for von Willebrand disease, particularly for patients with inhibitors to plasma-derived proteins. It offers flexible dosing, can be paired with recombinant FVIII, and is recommended by guidelines for precise VWF and FVIII management. The single review gave it a 4 out of 5 rating, suggesting a positive assessment of its clinical utility.
No reviews yet.
Be the first to share your experience with this treatment. Your insights help others make informed decisions about their care.
Reviews
Filter by reviewer type Pro